These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39215949)

  • 1. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ; Merola JF; Tanaka Y; Gossec L; McInnes IB; Ritchlin CT; Landewé RBM; Asahina A; Ink B; Heinrichs A; Bajracharya R; Shende V; Coarse J; Coates LC
    Rheumatol Ther; 2024 Oct; 11(5):1363-1382. PubMed ID: 39215949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
    Gossec L; Orbai AM; de Wit M; Coates LC; Ogdie A; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    Rheumatology (Oxford); 2024 Sep; 63(9):2399-2410. PubMed ID: 38754125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
    McInnes IB; Mease PJ; Tanaka Y; Gossec L; Husni ME; Kristensen LE; Warren RB; Ink B; Bajracharya R; Coarse J; Gottlieb AB
    ACR Open Rheumatol; 2024 Nov; 6(11):720-731. PubMed ID: 39077886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
    Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT; Coates LC; McInnes IB; Mease PJ; Merola JF; Tanaka Y; Asahina A; Gossec L; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Landewé RB
    Ann Rheum Dis; 2023 Nov; 82(11):1404-1414. PubMed ID: 37696588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Jun; 11(3):817-828. PubMed ID: 38446397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
    Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1403-1412. PubMed ID: 39120849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME; Mease PJ; Merola JF; Tillett W; Goldammer N; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39313302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
    Coates LC; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Orbai AM; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Merola JF
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
    Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1413-1423. PubMed ID: 39120848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
    Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
    J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab: A Review in Psoriatic Arthritis.
    Nie T; Shirley M
    Drugs; 2024 May; 84(5):587-598. PubMed ID: 38703349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
    Rheumatology (Oxford); 2024 Jul; 63(7):1779-1789. PubMed ID: 38218744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis.
    Kivitz A; Ellis AM; Shende V; Lambert J; Tatla D
    Patient Prefer Adherence; 2023; 17():2451-2461. PubMed ID: 37808274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.